|
|
Principal Investigator:
Michael Rosenzweig, MD
|
Sponsor: Cooperative Group
|
|
Title:
|
SWOG S1211: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
|
|
|
|
|
Principal Investigator:
Vincent Chung, MD
|
Sponsor: Industrial
|
|
Title:
|
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination with Docetaxel in the Treatment of Patients with Advanced Solid Tumors
|
|
|
|
|
Principal Investigator:
Leslie Popplewell, MD
|
Sponsor: NCI Approved External Peer Review
|
|
Title:
|
PHI-69, NCI #9197: A Phase I study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma
|
|
|
|
|
Principal Investigator:
Anthony Stein, MD
|
Sponsor: Industrial
|
|
Title:
|
An Open-Label, Phase 1/2 Study of PD-616 and Low-dose Cytarabine in Patients with Untreated or Relapsed/Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
|
|
|
|
Principal Investigator:
Robert Chen, MD
|
Sponsor: Industrial
|
|
Title:
|
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients with B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
|
|
|
|
|
Principal Investigator:
Robert Chen, MD
|
Sponsor: Industrial
|
|
Title:
|
Phase 1B Open-Label Study of the Safety and Clinical Activity of Crizotinib (PF-02341066) in Tumors with Genetic Events Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
|
|
|
|
|
Principal Investigator:
Marianna Koczywas, MD
|
Sponsor: NCI Approved External Peer Review
|
|
Title:
|
PHI-68, NCI #9152: A Phase I Study of ARQ 197 in Combination with IV Topotecan in Advanced Solid Tumors with an Expansion Cohort in Small Cell Lung Cancer
|
|
|
|
|
Principal Investigator:
Ryotaro Nakamura, MD
|
Sponsor: Institutional
|
|
Title:
|
A Phase I Trial To Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected with PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
|
|
|
|
|
Principal Investigator:
George Somlo, MD
|
Sponsor: Industrial
|
|
Title:
|
A Phase I/IIa Multi-Dose Escalation Study of BT062 in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma
|
|
|
|
|
Principal Investigator:
Vincent Chung, MD
|
Sponsor: Industrial
|
|
Title:
|
An Open-Label Phase I Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects with Cancer Who Also Have Impaired Renal Function
|
|
|
|
|
Principal Investigator:
Tanya Siddiqi, MD
|
Sponsor: NCI Approved External Peer Review
|
|
Title:
|
PHI-67, NCI #9091: Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination with the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
|
|
|
|
|
Principal Investigator:
Sumanta Pal, MD
|
Sponsor: Industrial
|
|
Title:
|
A Phase I Study of Nivolumab (BMS-936558) Plus Sunitinib, Paxopanib or Ipilamumab in Subjects with Metastatic Renal Cell Carcinoma
|
|
|
|
|
Principal Investigator:
Joanne Mortimer, MD
|
Sponsor: Industrial
|
|
Title:
|
A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies
|
|
|
|
|
Principal Investigator:
Samer Khaled, MD
|
Sponsor: Industrial
|
|
Title:
|
A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects with Acute Myeloid Leukemia Who Have Been Treated with an Allogeneic Hematopoietic Stem Cell Transplant
|
|
|
|
|
Principal Investigator:
Steven Chen, MD
|
Sponsor: NCI Approved External Peer Review
|
|
Title:
|
Reducing Extremity Lymphedema through Axillary Lymphatic Preservation Surgery
|
|
|
|
|
Principal Investigator:
Michael Rosenzweig, MD
|
Sponsor: Industrial
|
|
Title:
|
A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
|
|
|
|
|
Principal Investigator:
Amrita Krishnan, MD
|
Sponsor: Industrial
|
|
Title:
|
An Open Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF-4539A in Patients with Relapsed or Refractory Multiple Myeloma
|
|
|
|
|
Principal Investigator:
Leslie Popplewell, MD
|
Sponsor: Industrial
|
|
Title:
|
An Open-Label, Single-arm, Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma
|
|
|
|
|
Principal Investigator:
Myo Htut, MD
|
Sponsor: Industrial
|
|
Title:
|
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
|
|
|
|
|
Principal Investigator:
Vincent Chung, MD
|
Sponsor: NCI Approved External Peer Review
|
|
Title:
|
PHI-66 NCI#8846- Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction
|
|
|
|
|
Principal Investigator:
Vincent Chung, MD
|
Sponsor: NCI Approved External Peer Review
|
|
Title:
|
PHI-65, NCI #8808: An Early Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic Renal Dysfunction and Solid Tumors
|
|
|
|
|
Principal Investigator:
Leslie Popplewell, MD
|
Sponsor: Cooperative Group
|
|
Title:
|
SWOG S0806: A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) In Combination with Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
|
|
|
|
|
Principal Investigator:
Clayton Lau, MD
|
Sponsor: Institutional
|
|
Title:
|
A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging of Renal Cortical Tumors
|
|
|
|
|
Principal Investigator:
Myo Htut, MD
|
Sponsor: Industrial
|
|
Title:
|
A Phase I Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (Protocol ARRAY-520-111)
|
|
|
|
|
Principal Investigator:
Vincent Chung, MD
|
Sponsor: Institutional
|
|
Title:
|
A Phase I Study of an MVA Vaccine Targeting P53 in Cancer
|
|
|
|
|